NDA 021998 · Fdn Consumer
Plan B One-Step
Levonorgestrel · Oral · Progestin; Progestin-containing Intrauterine System
Last checked: Nov 19, 2026Latest source record: Dec 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jul 10, 2009
Approved uses
3
Original approval plus efficacy supplements
Registered trials
354
70 Phase 3, 26 recruiting
FAERS reports
42,154
4,490 serious, 59 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 24, 2023.
Use for women to reduce chance of pregnancy after unprotected sex (if a contraceptive failed or if you did not use birth control)
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 20, 2013 Supplement 3 · Efficacy LetterLabel
- Apr 30, 2013 Supplement 2 · Efficacy LabelReviewLetter
- Jul 10, 2009 Original approval · Type 3 - New Dosage Form LabelReviewPediatric Medical Review
1 products under this application
- PLAN B ONE-STEP · LEVONORGESTREL 1.5MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Levonorgestrel" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00006324 · 6,360 participants · Start Dec 1999
Drug: Ethinyl estradiol/levonorgestrel; Medroxyprogesterone acetate · For: HIV Infections
Sites: Research Triangle Park, North Carolina
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of PregnancyPivotal-lookingCompleted
Teva Women's HealthTeva (TEVA)
NCT00996580 · 3,597 participants · Start Oct 2009 · Primary completion Sep 2011
Drug: DR-103 · For: Pregnancy Prevention
Sites: Montgomery, Alabama; Phoenix, Arizona; Tucson, Arizona · 94 sites in all
- Levonorgestrel Contraceptive Intrauterine Systems (LCS) Pearl Index StudyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00528112 · 2,885 participants · Start Aug 2007 · Primary completion Jul 2011
Drug: LCS12; LCS16 · For: Contraception
Sites: Mobile, Alabama; Glendale, Arizona; Phoenix, Arizona · 136 sites in all
- Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral ContraceptivePivotal-lookingCompleted
Duramed ResearchIndustry
NCT00196326 · 2,235 participants · Start Jun 2005 · Primary completion Jun 2007
Drug: DR-1011 · For: Contraception
Sites: Huntsville, Alabama; Phoenix, Arizona; Tucson, Arizona · 55 sites in all
- Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency ContraceptionPivotal-lookingCompleted
HRA PharmaIndustry
NCT00551616 · 2,221 participants · Start Apr 2007 · Primary completion Apr 2009
Drug: CDB-2914; Levonorgestrel · For: Contraception
Sites: Los Angeles, California; Santa Monica, California; Boulder, Colorado · 33 sites in all
- Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery SystemPivotal-lookingCompleted
Agile TherapeuticsIndustry
NCT02158572 · 2,032 participants · Start Aug 2014 · Primary completion Nov 2016
Drug: AG200-15 · For: Healthy
- Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)Pivotal-lookingTerminated
Organon and CoIndustry
NCT02616146 · 2,016 participants · Start Dec 1, 2015 · Primary completion Oct 6, 2016
Drug: ENG-E2 125 μg/300 μg vaginal ring; LNG-EE 150 μg/30 μg COC · For: Contraception
Sites: Vienna, Austria; San José, Costa Rica; Glostrup Municipality, Denmark · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- menstruation irregular13,709
- vaginal haemorrhage7,830
- nausea4,998
- menstruation delayed4,893
- dysmenorrhoea3,952
- vomiting3,321
- headache2,373
- pelvic pain2,274
- fatigue2,098
- pregnancy after post coital contraception1,973
- drug ineffective1,926
- dizziness1,914
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 39 |
| 2006 | 37 |
| 2007 | 27 |
| 2008 | 22 |
| 2009 | 50 |
| 2010 | 85 |
| 2011 | 6,105 |
| 2012 | 4,981 |
| 2013 | 4,226 |
| 2014 | 4,720 |
| 2015 | 4,169 |
| 2016 | 3,887 |
| 2017 | 2,558 |
| 2018 | 1,718 |
| 2019 | 2,548 |
| 2020 | 2,075 |
| 2021 | 665 |
| 2022 | 1,142 |
| 2023 | 949 |
| 2024 | 939 |
| 2025 | 752 |
| 2026 | 421 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.
Dragoman MV, Tepper NK, Fu R, et al. · Int J Gynaecol Obstet 2018 · Meta-Analysis, Systematic Review
- Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis.
Barrionuevo P, Nabhan M, Altayar O, et al. · J Clin Endocrinol Metab 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Combined oral contraceptives: venous thrombosis.
de Bastos M, Stegeman BH, Rosendaal FR, et al. · Cochrane Database Syst Rev 2014 · Research Support, Non-U.S. Gov't, Systematic Review
- Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose.
Oedingen C, Scholz S, Razum O · Thromb Res 2018 · Meta-Analysis, Systematic Review
- Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis.
Martínez F, Ramírez I, Pérez-Campos E, et al. · Eur J Contracept Reprod Health Care 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A systematic review and meta-analysis of attitude and knowledge involving emergency oral contraceptive use in patients and healthcare providers.
Leelakanok N, Parmontree P, Petchsomrit A, et al. · Int J Clin Pharm 2022 · Meta-Analysis, Systematic Review
Sponsor: Fdn Consumer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.